RxDoctor Payments Data

Gary Greenspan, MD

Internal Medicine · Bratenahl, OHNPI 1164468120

Payments from drug & device makers

$1,331in general payments, 2019–2025

Across 42 payments — averaging $31.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$319
  • Novo Nordisk$166
  • Amgen$150
  • E.r. Squibb & Sons, L.L.C.$130
  • Sanofi$129
  • Bayer$125
  • plus $313 from 8 others

What the payments were for

  • Food & beverage$1,331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,331 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$23,390
Medicare patients
131
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$94,466
EliquisApixaban103$83,763
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$50,501
JardianceEmpagliflozin67$46,896
PerserisRisperidone12$36,976
LinzessLinaclotide65$36,223
JanuviaSitagliptin Phosphate31$36,162
OzempicSemaglutide19$34,213
Chlorpromazine Hcl88$28,874
Divalproex Sodium400$27,230
FanaptIloperidone14$27,078
NuedextaDextromethorphan Hbr/Quinidine14$20,406
KonvomepOmeprazole/Sodium Bicarbonate64$19,408
XareltoRivaroxaban19$18,131
Oxtellar XrOxcarbazepine17$17,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$319$83,763103 claims
AbbVieLinzess, Lumigan$17$41,03983 claims
Novo NordiskOzempic$166$34,21319 claims
Vanda Pharmaceuticals Inc.Fanapt$70$27,07814 claims
Johnson & JohnsonXarelto$13$18,13119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Bratenahl

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →